Product Information
MEXILETINE 200 MG CAPSULE is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.2574 per EA under NDC 00093874001. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on May 16, 1995. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
200 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093874001
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MEXILETINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA074377FDA Approved
5/16/1995
TE Code
AB
On Market Since
6/5/1995
Pharmacological Classes
Price Statistics
The NADAC for MEXILETINE 200 MG CAPSULE has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 32.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2574 per EA |
|---|---|
| All-time high | $1.1622 (Aug 14, 2019) |
| All-time low | $0.2472 (May 21, 2025) |
| 52-week high | $0.2971 |
| 52-week low | $0.2570 |
| Median price | $0.7806 |
| Average price | $0.7130 |
| Largest weekly change | +47.3% (Sep 17, 2014) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Mexiletine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antiarrhythmic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MEXILETINE 200 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for MEXILETINE 200 MG CAPSULE, manufactured by Teva Pharmaceuticals USA Inc., is $0.2574 per EA (NDC 00093874001), effective Sep 30, 2026.
How has the price of MEXILETINE 200 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for MEXILETINE 200 MG CAPSULE has declined 32.5%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for MEXILETINE 200 MG CAPSULE?
Since Nov 28, 2013, the NADAC for MEXILETINE 200 MG CAPSULE has ranged from a low of $0.2472 (May 21, 2025) to a high of $1.1622 (Aug 14, 2019), with a median of $0.7806 per EA.
Are there cheaper alternatives to MEXILETINE 200 MG CAPSULE?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as MEXILETINE 200 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures MEXILETINE 200 MG CAPSULE?
MEXILETINE 200 MG CAPSULE (NDC 00093874001) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.